news

  • 28 March 2018
    Preliminary long-term data for WTX101 in Wilson Disease accepted as a late-breaker presentation at EASL Annual Meeting

    Wilson Therapeutics AB (publ), announced today that preliminary long-term efficacy and safety data from the ongoing extension phase of the company’s Phase 2 trial of WTX101 (bis-choline tetrathiomolybdate), an investigational first-in-class copper-protein-binding agent under investigation as a novel therapy for Wilson Disease, has been accepted as a late-breaker poster presentation at The International Liver Congress™ 2018, the Annual Meeting of the European Association for the Study of the Liver (EASL) in Paris, France, 11-15 April, 2018.

    An abstract of the poster is available today, highlighting that the initial improvements in free copper levels, hepatic status and neurological status observed at week 24 and 48 were preserved or further improved after once-daily treatment for 72 weeks with WTX101. As reported previously, mean levels of non-ceruloplasmin bound copper (NCCcorrected) were significantly reduced in the Phase 2 study from 3.6 µM at baseline to 0.9 µM at week 24, and to 0.5 µM at week 48. The data that will be presented at EASL demonstrate that copper levels continued to remain controlled at week 72 at 0.5 µM. Continuous improvements in disability and neurological status were observed in most patients. Liver function tests (INR, ALT levels, albumin) and MELD score improved or remained unchanged between week 24 and week 72, indicating stabilization of liver function. The poster will also highlight the encouraging long-term safety profile of WTX101. Further details will be made available when the poster is presented.